{
    "info": {
        "nct_id": "NCT03781063",
        "official_title": "An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation",
        "inclusion_criteria": "1. Pre- or postmenopausal.\n\n   Postmenopausal women are defined as:\n   1. ≥60 years of age with no vaginal bleeding over the prior year, or\n   2. <60 years with \"premature menopause\" or \"premature ovarian failure\" manifest itself with secondary amenorrhea for at least 1 year and follicle stimulating hormone (FSH) and estradiol levels in the postmenopausal range according to institutional standards, or\n   3. surgical menopause with bilateral oophorectomy. Note: premenopausal women who meet all of the other entry criteria must be maintained on ovarian suppression (such as Lupron) during the study and subjects counseled to use appropriate contraception to prevent pregnancy.\n2. If possible, a biopsy of metastatic breast cancer tissue will be obtained to provide histological or cytological confirmation of ER+ and HER2- disease as assessed by a local laboratory, according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines, using slides, paraffin blocks, or paraffin samples. If a biopsy is not possible, the ER and HER2 status from the tissue obtained at the time of the original diagnosis must confirm that the subject's cancer is ER+ and HER2-.\n3. Locally advanced or metastatic breast cancer with radiological or clinical evidence of progression on an AI in combination with a CDK 4/6 inhibitor for advanced breast cancer with demonstrated prior sensitivity to endocrine therapy (recurrence or progression after at least 12 months of treatment in the metastatic setting).\n4. Locally advanced or metastatic breast cancer with either measurable (according to RECIST 1.1) or non-measurable lesions.\n5. At least one or more of the following point ESR1 mutations as assessed in cell-free circulating tumor DNA (ctDNA) obtained from a blood (plasma) or tissue sample: Y537S, Y537C, D538G, E380Q, S463P, V534E, P535H, L536H, L536P, L536R, L536Q, or Y537N. The ctDNA sample collection must be obtained within 30 days prior to randomization to determine eligibility and baseline. Note: a prior genomic test confirming that the subject has an ESR1 mutation can be used to determine eligibility; however, an ESR1 sample must also be collected within 30 days of randomization.\n6. Subjects who have not received cytotoxic chemotherapy or those who have received one cytotoxic chemotherapy regimen in the neo-adjuvant or adjuvant setting prior to entry into the trial and/or no more than one chemotherapy regimen for metastatic breast cancer. Subjects must be free of all chemotherapy acute toxicity excluding alopecia and Grade II peripheral neuropathy before study entry.\n7. ECOG performance score of 0 or 1.\n8. Adequate organ function as shown by:\n\n   1. absolute neutrophil count (ANC) >/=1,500 cells/mm3\n   2. platelet count ≤100,000 cells/mm3\n   3. hemoglobin >/=9.0 g/dl\n   4. ALT and AST levels ≤2.5 upper limit of normal (ULN) or ≤5 in the presence of visceral metastasis\n   5. total serum bilirubin ≤1.5 X ULN (≤ 3 X ULN for subjects known to have Gilbert Syndrome)\n   6. alkaline phosphatase level ≤ 2.5 X ULN\n   7. creatinine clearance of 40 ml/min or greater as calculated by the Cockcroft-Gault formula\n   8. International normalized ratio (INR), activated partial thromboplastin (aPTT), or partial thromboplastin time (PTT) <2.0 X ULN.\n9. Able to swallow tablets.\n10. Able to understand and voluntarily sign a written informed consent before any screening procedures.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Prior use of everolimus or other mammalian target of rapamycin (mTOR) inhibitor or phosphoinositide 3-kinase inhibitor (PI3K) inhibitors is excluded unless discontinued to reasons other than disease progression.\n2. Presence of brain metastasis.\n3. Lymphangitic carcinomatosis involving the lung.\n4. Impending visceral crisis in need of cytotoxic chemotherapy as assessed by the investigator.\n5. Radiotherapy within 30 days prior to randomization except in case of localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to randomization. Subjects must have recovered from radiotherapy toxicities prior to randomization.\n6. History of long QTC syndrome or a QTC of >480 ms.\n7. History of a pulmonary embolus (PE) or deep vein thrombosis (DVT) within the last 6 months or any known thrombophilia. Subjects stable on anti-coagulants for maintenance are eligible as long as the DVT and/or PE occurred >6 months prior to enrollment and there is no evidence for active thrombosis. The use of low dose ASA is permitted.\n8. Any significant co-morbidity that would impact the study or the subject's safety.\n9. History of a positive human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) at Screening. Subjects cured of hepatitis C (no viral load) are eligible.\n10. History of malignancy within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery, or early stage cervical cancer.\n11. History of vaginal bleeding over the last year unless it is documented that the bleeding was due to non-uterine causes (e.g. vaginal atrophy).\n12. Uncontrolled hypertension defined as sitting systolic pressure >160 mm Hg or diastolic pressure >100 mm Hg at Screening.\n13. History of non-compliance to medical regimens.\n14. Unwilling or unable to comply with the protocol.\n15. Current participation in any clinical research trial involving an investigational drug or device within the last 30 days.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "Postmenopausal women are defined as:",
                "criterions": [
                    {
                        "exact_snippets": "Postmenopausal women",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "postmenopausal"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Postmenopausal women",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "postmenopausal"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. hemoglobin >/=9.0 g/dl",
                "criterions": [
                    {
                        "exact_snippets": "hemoglobin >/=9.0 g/dl",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dl"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "hemoglobin >/=9.0 g/dl",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dl"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. ECOG performance score of 0 or 1.",
                "criterions": [
                    {
                        "exact_snippets": "ECOG performance score of 0 or 1",
                        "criterion": "ECOG performance score",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ECOG performance score of 0 or 1",
                        "criterion": "ECOG performance score",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. absolute neutrophil count (ANC) >/=1,500 cells/mm3",
                "criterions": [
                    {
                        "exact_snippets": "absolute neutrophil count (ANC) >/=1,500 cells/mm3",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "cells/mm3"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "absolute neutrophil count (ANC) >/=1,500 cells/mm3",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "cells/mm3"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Adequate organ function as shown by:",
                "criterions": [
                    {
                        "exact_snippets": "Adequate organ function",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Adequate organ function",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. International normalized ratio (INR), activated partial thromboplastin (aPTT), or partial thromboplastin time (PTT) <2.0 X ULN.",
                "criterions": [
                    {
                        "exact_snippets": "International normalized ratio (INR) ... <2.0 X ULN",
                        "criterion": "International normalized ratio (INR)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.0,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "activated partial thromboplastin (aPTT) ... <2.0 X ULN",
                        "criterion": "activated partial thromboplastin time (aPTT)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.0,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "partial thromboplastin time (PTT) <2.0 X ULN",
                        "criterion": "partial thromboplastin time (PTT)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.0,
                                "unit": "ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "International normalized ratio (INR) ... <2.0 X ULN",
                        "criterion": "International normalized ratio (INR)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.0,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "activated partial thromboplastin (aPTT) ... <2.0 X ULN",
                        "criterion": "activated partial thromboplastin time (aPTT)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.0,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "partial thromboplastin time (PTT) <2.0 X ULN",
                        "criterion": "partial thromboplastin time (PTT)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.0,
                                "unit": "ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Able to understand and voluntarily sign a written informed consent before any screening procedures.",
                "criterions": [
                    {
                        "exact_snippets": "Able to understand ... written informed consent",
                        "criterion": "ability to understand informed consent",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "voluntarily sign a written informed consent",
                        "criterion": "ability to voluntarily sign informed consent",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "before any screening procedures",
                        "criterion": "timing of informed consent",
                        "requirement": {
                            "requirement_type": "before screening procedures",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Able to understand ... written informed consent",
                        "criterion": "ability to understand informed consent",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "voluntarily sign a written informed consent",
                        "criterion": "ability to voluntarily sign informed consent",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "before any screening procedures",
                        "criterion": "timing of informed consent",
                        "requirement": {
                            "requirement_type": "before screening procedures",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. total serum bilirubin ≤1.5 X ULN (≤ 3 X ULN for subjects known to have Gilbert Syndrome)",
                "criterions": [
                    {
                        "exact_snippets": "total serum bilirubin ≤1.5 X ULN",
                        "criterion": "total serum bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "X ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "≤ 3 X ULN for subjects known to have Gilbert Syndrome",
                        "criterion": "total serum bilirubin in subjects with Gilbert Syndrome",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "X ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "≤ 3 X ULN for subjects known to have Gilbert Syndrome",
                    "criterion": "total serum bilirubin in subjects with Gilbert Syndrome",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "operator": "<=",
                            "value": 3,
                            "unit": "X ULN"
                        }
                    }
                },
                "then_criteria": null,
                "else_criteria": {
                    "exact_snippets": "total serum bilirubin ≤1.5 X ULN",
                    "criterion": "total serum bilirubin",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "operator": "<=",
                            "value": 1.5,
                            "unit": "X ULN"
                        }
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "6. alkaline phosphatase level ≤ 2.5 X ULN",
                "criterions": [
                    {
                        "exact_snippets": "alkaline phosphatase level ≤ 2.5 X ULN",
                        "criterion": "alkaline phosphatase level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "X ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "alkaline phosphatase level ≤ 2.5 X ULN",
                        "criterion": "alkaline phosphatase level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "X ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. surgical menopause with bilateral oophorectomy. Note: premenopausal women who meet all of the other entry criteria must be maintained on ovarian suppression (such as Lupron) during the study and subjects counseled to use appropriate contraception to prevent pregnancy.",
                "criterions": [
                    {
                        "exact_snippets": "surgical menopause with bilateral oophorectomy",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "surgical menopause with bilateral oophorectomy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "premenopausal women who meet all of the other entry criteria must be maintained on ovarian suppression (such as Lupron) during the study",
                        "criterion": "ovarian suppression",
                        "requirement": {
                            "requirement_type": "maintenance during the study",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "subjects counseled to use appropriate contraception to prevent pregnancy",
                        "criterion": "contraception counseling",
                        "requirement": {
                            "requirement_type": "counseling to use contraception",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "surgical menopause with bilateral oophorectomy",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "surgical menopause with bilateral oophorectomy",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "premenopausal women who meet all of the other entry criteria must be maintained on ovarian suppression (such as Lupron) during the study",
                                "criterion": "ovarian suppression",
                                "requirement": {
                                    "requirement_type": "maintenance during the study",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "subjects counseled to use appropriate contraception to prevent pregnancy",
                                "criterion": "contraception counseling",
                                "requirement": {
                                    "requirement_type": "counseling to use contraception",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. ALT and AST levels ≤2.5 upper limit of normal (ULN) or ≤5 in the presence of visceral metastasis",
                "criterions": [
                    {
                        "exact_snippets": "ALT and AST levels ≤2.5 upper limit of normal (ULN) or ≤5 in the presence of visceral metastasis",
                        "criterion": "ALT level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "ALT and AST levels ≤2.5 upper limit of normal (ULN) or ≤5 in the presence of visceral metastasis",
                        "criterion": "ALT level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "ALT and AST levels ≤2.5 upper limit of normal (ULN) or ≤5 in the presence of visceral metastasis",
                        "criterion": "AST level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "ALT and AST levels ≤2.5 upper limit of normal (ULN) or ≤5 in the presence of visceral metastasis",
                        "criterion": "AST level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "ALT and AST levels ≤2.5 upper limit of normal (ULN) or ≤5 in the presence of visceral metastasis",
                                "criterion": "ALT level",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 2.5,
                                                "unit": "ULN"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "exact_snippets": "ALT and AST levels ≤2.5 upper limit of normal (ULN) or ≤5 in the presence of visceral metastasis",
                                "criterion": "AST level",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 2.5,
                                                "unit": "ULN"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "ALT and AST levels ≤2.5 upper limit of normal (ULN) or ≤5 in the presence of visceral metastasis",
                                "criterion": "ALT level",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 5,
                                                "unit": "ULN"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "exact_snippets": "ALT and AST levels ≤2.5 upper limit of normal (ULN) or ≤5 in the presence of visceral metastasis",
                                "criterion": "AST level",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 5,
                                                "unit": "ULN"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. creatinine clearance of 40 ml/min or greater as calculated by the Cockcroft-Gault formula",
                "criterions": [
                    {
                        "exact_snippets": "creatinine clearance of 40 ml/min or greater as calculated by the Cockcroft-Gault formula",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "ml/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "creatinine clearance of 40 ml/min or greater as calculated by the Cockcroft-Gault formula",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "creatinine clearance of 40 ml/min or greater as calculated by the Cockcroft-Gault formula",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "ml/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "creatinine clearance of 40 ml/min or greater as calculated by the Cockcroft-Gault formula",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. <60 years with \"premature menopause\" or \"premature ovarian failure\" manifest itself with secondary amenorrhea for at least 1 year and follicle stimulating hormone (FSH) and estradiol levels in the postmenopausal range according to institutional standards, or",
                "criterions": [
                    {
                        "exact_snippets": "<60 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "maximum value",
                            "expected_value": {
                                "operator": "<",
                                "value": 60,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "\"premature menopause\" or \"premature ovarian failure\"",
                        "criterion": "premature menopause or premature ovarian failure",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "secondary amenorrhea for at least 1 year",
                        "criterion": "secondary amenorrhea",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "follicle stimulating hormone (FSH) and estradiol levels in the postmenopausal range according to institutional standards",
                        "criterion": "FSH and estradiol levels",
                        "requirement": {
                            "requirement_type": "range",
                            "expected_value": "postmenopausal range according to institutional standards"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "<60 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "maximum value",
                            "expected_value": {
                                "operator": "<",
                                "value": 60,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "\"premature menopause\" or \"premature ovarian failure\"",
                        "criterion": "premature menopause or premature ovarian failure",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "secondary amenorrhea for at least 1 year",
                        "criterion": "secondary amenorrhea",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "follicle stimulating hormone (FSH) and estradiol levels in the postmenopausal range according to institutional standards",
                        "criterion": "FSH and estradiol levels",
                        "requirement": {
                            "requirement_type": "range",
                            "expected_value": "postmenopausal range according to institutional standards"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Able to swallow tablets.",
                "criterions": [
                    {
                        "exact_snippets": "Able to swallow tablets",
                        "criterion": "ability to swallow tablets",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Able to swallow tablets",
                        "criterion": "ability to swallow tablets",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must be FEMALE",
                "criterions": [
                    {
                        "exact_snippets": "Must be FEMALE",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Must be FEMALE",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "6. History of long QTC syndrome or a QTC of >480 ms.",
                "criterions": [
                    {
                        "exact_snippets": "History of long QTC syndrome",
                        "criterion": "long QTC syndrome",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "QTC of >480 ms",
                        "criterion": "QTC interval",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "ms"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of long QTC syndrome",
                        "criterion": "long QTC syndrome",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "QTC of >480 ms",
                        "criterion": "QTC interval",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "ms"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. History of a positive human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) at Screening. Subjects cured of hepatitis C (no viral load) are eligible.",
                "criterions": [
                    {
                        "exact_snippets": "History of a positive human immunodeficiency virus (HIV) ... at Screening",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "history of positivity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of a positive ... hepatitis B virus (HBV) ... at Screening",
                        "criterion": "hepatitis B virus infection",
                        "requirement": {
                            "requirement_type": "history of positivity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of a positive ... hepatitis C virus (HCV) at Screening. Subjects cured of hepatitis C (no viral load) are eligible.",
                        "criterion": "hepatitis C virus infection",
                        "requirement": {
                            "requirement_type": "history of positivity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of a positive ... hepatitis C virus (HCV) at Screening. Subjects cured of hepatitis C (no viral load) are eligible.",
                        "criterion": "hepatitis C virus infection",
                        "requirement": {
                            "requirement_type": "cure status",
                            "expected_value": "Subjects cured of hepatitis C (no viral load) are eligible"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of a positive human immunodeficiency virus (HIV) ... at Screening",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "history of positivity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of a positive ... hepatitis B virus (HBV) ... at Screening",
                        "criterion": "hepatitis B virus infection",
                        "requirement": {
                            "requirement_type": "history of positivity",
                            "expected_value": true
                        }
                    },
                    {
                        "condition": {
                            "exact_snippets": "History of a positive ... hepatitis C virus (HCV) at Screening. Subjects cured of hepatitis C (no viral load) are eligible.",
                            "criterion": "hepatitis C virus infection",
                            "requirement": {
                                "requirement_type": "history of positivity",
                                "expected_value": true
                            }
                        },
                        "then_criteria": {
                            "not_criteria": {
                                "exact_snippets": "History of a positive ... hepatitis C virus (HCV) at Screening. Subjects cured of hepatitis C (no viral load) are eligible.",
                                "criterion": "hepatitis C virus infection",
                                "requirement": {
                                    "requirement_type": "cure status",
                                    "expected_value": "Subjects cured of hepatitis C (no viral load) are eligible"
                                }
                            }
                        },
                        "else_criteria": null
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "11. History of vaginal bleeding over the last year unless it is documented that the bleeding was due to non-uterine causes (e.g. vaginal atrophy).",
                "criterions": [
                    {
                        "exact_snippets": "History of vaginal bleeding over the last year",
                        "criterion": "vaginal bleeding",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "unless it is documented that the bleeding was due to non-uterine causes (e.g. vaginal atrophy)",
                        "criterion": "cause of vaginal bleeding",
                        "requirement": {
                            "requirement_type": "cause",
                            "expected_value": "non-uterine"
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "History of vaginal bleeding over the last year",
                    "criterion": "vaginal bleeding",
                    "requirement": {
                        "requirement_type": "history_within_timeframe",
                        "expected_value": {
                            "operator": "=",
                            "value": 1,
                            "unit": "year"
                        }
                    }
                },
                "then_criteria": {
                    "not_criteria": {
                        "exact_snippets": "unless it is documented that the bleeding was due to non-uterine causes (e.g. vaginal atrophy)",
                        "criterion": "cause of vaginal bleeding",
                        "requirement": {
                            "requirement_type": "cause",
                            "expected_value": "non-uterine"
                        }
                    }
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "15. Current participation in any clinical research trial involving an investigational drug or device within the last 30 days.",
                "criterions": [
                    {
                        "exact_snippets": "Current participation in any clinical research trial involving an investigational drug or device within the last 30 days.",
                        "criterion": "participation in clinical research trial involving an investigational drug or device",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Current participation in any clinical research trial involving an investigational drug or device within the last 30 days.",
                        "criterion": "participation in clinical research trial involving an investigational drug or device",
                        "requirement": {
                            "requirement_type": "current_participation",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Current participation in any clinical research trial involving an investigational drug or device within the last 30 days.",
                        "criterion": "participation in clinical research trial involving an investigational drug or device",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Current participation in any clinical research trial involving an investigational drug or device within the last 30 days.",
                        "criterion": "participation in clinical research trial involving an investigational drug or device",
                        "requirement": {
                            "requirement_type": "current_participation",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Lymphangitic carcinomatosis involving the lung.",
                "criterions": [
                    {
                        "exact_snippets": "Lymphangitic carcinomatosis involving the lung",
                        "criterion": "lymphangitic carcinomatosis involving the lung",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Lymphangitic carcinomatosis involving the lung",
                    "criterion": "lymphangitic carcinomatosis involving the lung",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "13. History of non-compliance to medical regimens.",
                "criterions": [
                    {
                        "exact_snippets": "History of non-compliance to medical regimens.",
                        "criterion": "non-compliance to medical regimens",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "History of non-compliance to medical regimens.",
                        "criterion": "non-compliance to medical regimens",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Impending visceral crisis in need of cytotoxic chemotherapy as assessed by the investigator.",
                "criterions": [
                    {
                        "exact_snippets": "Impending visceral crisis",
                        "criterion": "impending visceral crisis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "in need of cytotoxic chemotherapy",
                        "criterion": "need for cytotoxic chemotherapy",
                        "requirement": {
                            "requirement_type": "necessity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "as assessed by the investigator",
                        "criterion": "investigator assessment",
                        "requirement": {
                            "requirement_type": "assessment",
                            "expected_value": "by investigator"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Impending visceral crisis",
                                "criterion": "impending visceral crisis",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "in need of cytotoxic chemotherapy",
                                "criterion": "need for cytotoxic chemotherapy",
                                "requirement": {
                                    "requirement_type": "necessity",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "as assessed by the investigator",
                        "criterion": "investigator assessment",
                        "requirement": {
                            "requirement_type": "assessment",
                            "expected_value": "by investigator"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Presence of brain metastasis.",
                "criterions": [
                    {
                        "exact_snippets": "Presence of brain metastasis",
                        "criterion": "brain metastasis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Presence of brain metastasis",
                    "criterion": "brain metastasis",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "12. Uncontrolled hypertension defined as sitting systolic pressure >160 mm Hg or diastolic pressure >100 mm Hg at Screening.",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled hypertension defined as sitting systolic pressure >160 mm Hg",
                        "criterion": "sitting systolic blood pressure",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 160,
                                "unit": "mm Hg"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled hypertension defined as ... diastolic pressure >100 mm Hg at Screening",
                        "criterion": "diastolic blood pressure",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "mm Hg"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Uncontrolled hypertension defined as sitting systolic pressure >160 mm Hg",
                        "criterion": "sitting systolic blood pressure",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 160,
                                "unit": "mm Hg"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled hypertension defined as ... diastolic pressure >100 mm Hg at Screening",
                        "criterion": "diastolic blood pressure",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "mm Hg"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "14. Unwilling or unable to comply with the protocol.",
                "criterions": [
                    {
                        "exact_snippets": "Unwilling or unable to comply with the protocol",
                        "criterion": "willingness or ability to comply with the protocol",
                        "requirement": {
                            "requirement_type": "willingness or ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Unwilling or unable to comply with the protocol",
                    "criterion": "willingness or ability to comply with the protocol",
                    "requirement": {
                        "requirement_type": "willingness or ability",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "5. Radiotherapy within 30 days prior to randomization except in case of localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to randomization. Subjects must have recovered from radiotherapy toxicities prior to randomization.",
                "criterions": [
                    {
                        "exact_snippets": "Radiotherapy within 30 days prior to randomization",
                        "criterion": "radiotherapy",
                        "requirement": {
                            "requirement_type": "time since last radiotherapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "except in case of localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to randomization",
                        "criterion": "localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture",
                        "requirement": {
                            "requirement_type": "time since completion of localized radiotherapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Subjects must have recovered from radiotherapy toxicities prior to randomization",
                        "criterion": "recovery from radiotherapy toxicities",
                        "requirement": {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "Radiotherapy within 30 days prior to randomization",
                                    "criterion": "radiotherapy",
                                    "requirement": {
                                        "requirement_type": "time since last radiotherapy",
                                        "expected_value": {
                                            "operator": ">=",
                                            "value": 30,
                                            "unit": "days"
                                        }
                                    }
                                },
                                {
                                    "not_criteria": {
                                        "exact_snippets": "except in case of localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to randomization",
                                        "criterion": "localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture",
                                        "requirement": {
                                            "requirement_type": "time since completion of localized radiotherapy",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 7,
                                                "unit": "days"
                                            }
                                        }
                                    }
                                }
                            ]
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "Subjects must have recovered from radiotherapy toxicities prior to randomization",
                            "criterion": "recovery from radiotherapy toxicities",
                            "requirement": {
                                "requirement_type": "recovery status",
                                "expected_value": true
                            }
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "3. Locally advanced or metastatic breast cancer with radiological or clinical evidence of progression on an AI in combination with a CDK 4/6 inhibitor for advanced breast cancer with demonstrated prior sensitivity to endocrine therapy (recurrence or progression after at least 12 months of treatment in the metastatic setting).",
                "criterions": [
                    {
                        "exact_snippets": "Locally advanced or metastatic breast cancer",
                        "criterion": "breast cancer stage",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "radiological or clinical evidence of progression on an AI in combination with a CDK 4/6 inhibitor",
                        "criterion": "progression on AI and CDK 4/6 inhibitor",
                        "requirement": {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "radiological or clinical evidence of progression on an AI in combination with a CDK 4/6 inhibitor",
                        "criterion": "progression on AI and CDK 4/6 inhibitor",
                        "requirement": {
                            "requirement_type": "treatment",
                            "expected_value": [
                                "aromatase inhibitor (AI)",
                                "CDK 4/6 inhibitor"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "demonstrated prior sensitivity to endocrine therapy (recurrence or progression after at least 12 months of treatment in the metastatic setting)",
                        "criterion": "prior sensitivity to endocrine therapy",
                        "requirement": {
                            "requirement_type": "sensitivity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "demonstrated prior sensitivity to endocrine therapy (recurrence or progression after at least 12 months of treatment in the metastatic setting)",
                        "criterion": "prior sensitivity to endocrine therapy",
                        "requirement": {
                            "requirement_type": "duration of prior endocrine therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "demonstrated prior sensitivity to endocrine therapy (recurrence or progression after at least 12 months of treatment in the metastatic setting)",
                        "criterion": "prior sensitivity to endocrine therapy",
                        "requirement": {
                            "requirement_type": "setting",
                            "expected_value": "metastatic"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Pre- or postmenopausal.",
                "criterions": [
                    {
                        "exact_snippets": "Pre- or postmenopausal.",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": [
                                "premenopausal",
                                "postmenopausal"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "6. Subjects who have not received cytotoxic chemotherapy or those who have received one cytotoxic chemotherapy regimen in the neo-adjuvant or adjuvant setting prior to entry into the trial and/or no more than one chemotherapy regimen for metastatic breast cancer. Subjects must be free of all chemotherapy acute toxicity excluding alopecia and Grade II peripheral neuropathy before study entry.",
                "criterions": [
                    {
                        "exact_snippets": "Subjects who have not received cytotoxic chemotherapy or those who have received one cytotoxic chemotherapy regimen in the neo-adjuvant or adjuvant setting prior to entry into the trial and/or no more than one chemotherapy regimen for metastatic breast cancer.",
                        "criterion": "cytotoxic chemotherapy regimens received",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "=",
                                        "value": 0,
                                        "unit": "regimen"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Subjects who have not received cytotoxic chemotherapy or those who have received one cytotoxic chemotherapy regimen in the neo-adjuvant or adjuvant setting prior to entry into the trial and/or no more than one chemotherapy regimen for metastatic breast cancer.",
                        "criterion": "cytotoxic chemotherapy regimens received",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "=",
                                        "value": 1,
                                        "unit": "regimen"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Subjects who have not received cytotoxic chemotherapy or those who have received one cytotoxic chemotherapy regimen in the neo-adjuvant or adjuvant setting prior to entry into the trial and/or no more than one chemotherapy regimen for metastatic breast cancer.",
                        "criterion": "cytotoxic chemotherapy regimens received",
                        "requirement": {
                            "requirement_type": "setting",
                            "expected_value": [
                                "neo-adjuvant",
                                "adjuvant",
                                "metastatic breast cancer"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Subjects who have not received cytotoxic chemotherapy or those who have received one cytotoxic chemotherapy regimen in the neo-adjuvant or adjuvant setting prior to entry into the trial and/or no more than one chemotherapy regimen for metastatic breast cancer.",
                        "criterion": "cytotoxic chemotherapy regimens received",
                        "requirement": {
                            "requirement_type": "quantity (metastatic breast cancer)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "regimen"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Subjects must be free of all chemotherapy acute toxicity excluding alopecia and Grade II peripheral neuropathy before study entry.",
                        "criterion": "chemotherapy acute toxicity",
                        "requirement": {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Subjects must be free of all chemotherapy acute toxicity excluding alopecia and Grade II peripheral neuropathy before study entry.",
                        "criterion": "chemotherapy acute toxicity",
                        "requirement": {
                            "requirement_type": "exceptions",
                            "expected_value": [
                                "alopecia",
                                "Grade II peripheral neuropathy"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "2. platelet count ≤100,000 cells/mm3",
                "criterions": [
                    {
                        "exact_snippets": "platelet count ≤100,000 cells/mm3",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 100000,
                                "unit": "cells/mm3"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "platelet count \u001c100,000 cells/mm3",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 100000,
                                "unit": "cells/mm3"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Locally advanced or metastatic breast cancer with either measurable (according to RECIST 1.1) or non-measurable lesions.",
                "criterions": [
                    {
                        "exact_snippets": "Locally advanced or metastatic breast cancer",
                        "criterion": "breast cancer stage",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "measurable (according to RECIST 1.1) or non-measurable lesions",
                        "criterion": "lesion measurability",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": [
                                "measurable (according to RECIST 1.1)",
                                "non-measurable"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "1. ≥60 years of age with no vaginal bleeding over the prior year, or",
                "criterions": [
                    {
                        "exact_snippets": "≥60 years of age",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "no vaginal bleeding over the prior year",
                        "criterion": "vaginal bleeding",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "no vaginal bleeding over the prior year",
                        "criterion": "vaginal bleeding",
                        "requirement": {
                            "requirement_type": "time period",
                            "expected_value": "prior year"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "\u001e60 years of age",
                                "criterion": "age",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 60,
                                        "unit": "years"
                                    }
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "no vaginal bleeding over the prior year",
                                        "criterion": "vaginal bleeding",
                                        "requirement": {
                                            "requirement_type": "presence",
                                            "expected_value": false
                                        }
                                    },
                                    {
                                        "exact_snippets": "no vaginal bleeding over the prior year",
                                        "criterion": "vaginal bleeding",
                                        "requirement": {
                                            "requirement_type": "time period",
                                            "expected_value": "prior year"
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. At least one or more of the following point ESR1 mutations as assessed in cell-free circulating tumor DNA (ctDNA) obtained from a blood (plasma) or tissue sample: Y537S, Y537C, D538G, E380Q, S463P, V534E, P535H, L536H, L536P, L536R, L536Q, or Y537N. The ctDNA sample collection must be obtained within 30 days prior to randomization to determine eligibility and baseline. Note: a prior genomic test confirming that the subject has an ESR1 mutation can be used to determine eligibility; however, an ESR1 sample must also be collected within 30 days of randomization.",
                "criterions": [
                    {
                        "exact_snippets": "At least one or more of the following point ESR1 mutations as assessed in cell-free circulating tumor DNA (ctDNA) obtained from a blood (plasma) or tissue sample: Y537S, Y537C, D538G, E380Q, S463P, V534E, P535H, L536H, L536P, L536R, L536Q, or Y537N.",
                        "criterion": "ESR1 point mutation in ctDNA",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "At least one or more of the following point ESR1 mutations as assessed in cell-free circulating tumor DNA (ctDNA) obtained from a blood (plasma) or tissue sample: Y537S, Y537C, D538G, E380Q, S463P, V534E, P535H, L536H, L536P, L536R, L536Q, or Y537N.",
                        "criterion": "ESR1 point mutation in ctDNA",
                        "requirement": {
                            "requirement_type": "mutation_type",
                            "expected_value": [
                                "Y537S",
                                "Y537C",
                                "D538G",
                                "E380Q",
                                "S463P",
                                "V534E",
                                "P535H",
                                "L536H",
                                "L536P",
                                "L536R",
                                "L536Q",
                                "Y537N"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "At least one or more of the following point ESR1 mutations as assessed in cell-free circulating tumor DNA (ctDNA) obtained from a blood (plasma) or tissue sample: Y537S, Y537C, D538G, E380Q, S463P, V534E, P535H, L536H, L536P, L536R, L536Q, or Y537N.",
                        "criterion": "ESR1 point mutation in ctDNA",
                        "requirement": {
                            "requirement_type": "sample_type",
                            "expected_value": [
                                "blood (plasma)",
                                "tissue"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "The ctDNA sample collection must be obtained within 30 days prior to randomization to determine eligibility and baseline.",
                        "criterion": "ctDNA sample collection timing",
                        "requirement": {
                            "requirement_type": "time_before_randomization",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "a prior genomic test confirming that the subject has an ESR1 mutation can be used to determine eligibility; however, an ESR1 sample must also be collected within 30 days of randomization.",
                        "criterion": "prior genomic test for ESR1 mutation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "an ESR1 sample must also be collected within 30 days of randomization.",
                        "criterion": "ESR1 sample collection timing",
                        "requirement": {
                            "requirement_type": "time_before_randomization",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "2. If possible, a biopsy of metastatic breast cancer tissue will be obtained to provide histological or cytological confirmation of ER+ and HER2- disease as assessed by a local laboratory, according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines, using slides, paraffin blocks, or paraffin samples. If a biopsy is not possible, the ER and HER2 status from the tissue obtained at the time of the original diagnosis must confirm that the subject's cancer is ER+ and HER2-.",
                "criterions": [
                    {
                        "exact_snippets": "a biopsy of metastatic breast cancer tissue will be obtained",
                        "criterion": "biopsy of metastatic breast cancer tissue",
                        "requirement": {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "histological or cytological confirmation of ER+ and HER2- disease as assessed by a local laboratory, according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines",
                        "criterion": "ER and HER2 status of metastatic breast cancer tissue",
                        "requirement": {
                            "requirement_type": "ER status",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "histological or cytological confirmation of ER+ and HER2- disease as assessed by a local laboratory, according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines",
                        "criterion": "ER and HER2 status of metastatic breast cancer tissue",
                        "requirement": {
                            "requirement_type": "HER2 status",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "histological or cytological confirmation of ER+ and HER2- disease as assessed by a local laboratory, according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines",
                        "criterion": "ER and HER2 status of metastatic breast cancer tissue",
                        "requirement": {
                            "requirement_type": "assessment method",
                            "expected_value": "local laboratory, ASCO/CAP guidelines"
                        }
                    },
                    {
                        "exact_snippets": "using slides, paraffin blocks, or paraffin samples",
                        "criterion": "sample type for biopsy",
                        "requirement": {
                            "requirement_type": "sample type",
                            "expected_value": [
                                "slides",
                                "paraffin blocks",
                                "paraffin samples"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "If a biopsy is not possible, the ER and HER2 status from the tissue obtained at the time of the original diagnosis must confirm that the subject's cancer is ER+ and HER2-",
                        "criterion": "ER and HER2 status of original diagnostic tissue",
                        "requirement": {
                            "requirement_type": "ER status",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "If a biopsy is not possible, the ER and HER2 status from the tissue obtained at the time of the original diagnosis must confirm that the subject's cancer is ER+ and HER2-",
                        "criterion": "ER and HER2 status of original diagnostic tissue",
                        "requirement": {
                            "requirement_type": "HER2 status",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "If a biopsy is not possible, the ER and HER2 status from the tissue obtained at the time of the original diagnosis must confirm that the subject's cancer is ER+ and HER2-",
                        "criterion": "ER and HER2 status of original diagnostic tissue",
                        "requirement": {
                            "requirement_type": "source",
                            "expected_value": "tissue obtained at the time of the original diagnosis"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "1. Prior use of everolimus or other mammalian target of rapamycin (mTOR) inhibitor or phosphoinositide 3-kinase inhibitor (PI3K) inhibitors is excluded unless discontinued to reasons other than disease progression.",
                "criterions": [
                    {
                        "exact_snippets": "Prior use of everolimus or other mammalian target of rapamycin (mTOR) inhibitor or phosphoinositide 3-kinase inhibitor (PI3K) inhibitors is excluded unless discontinued to reasons other than disease progression.",
                        "criterion": "prior use of everolimus, mTOR inhibitor, or PI3K inhibitor",
                        "requirement": {
                            "requirement_type": "prior use",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Prior use of everolimus or other mammalian target of rapamycin (mTOR) inhibitor or phosphoinositide 3-kinase inhibitor (PI3K) inhibitors is excluded unless discontinued to reasons other than disease progression.",
                        "criterion": "prior use of everolimus, mTOR inhibitor, or PI3K inhibitor",
                        "requirement": {
                            "requirement_type": "discontinuation reason",
                            "expected_value": "reasons other than disease progression"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Prior use of everolimus or other mammalian target of rapamycin (mTOR) inhibitor or phosphoinositide 3-kinase inhibitor (PI3K) inhibitors is excluded unless discontinued to reasons other than disease progression.",
                                "criterion": "prior use of everolimus, mTOR inhibitor, or PI3K inhibitor",
                                "requirement": {
                                    "requirement_type": "prior use",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Prior use of everolimus or other mammalian target of rapamycin (mTOR) inhibitor or phosphoinositide 3-kinase inhibitor (PI3K) inhibitors is excluded unless discontinued to reasons other than disease progression.",
                                "criterion": "prior use of everolimus, mTOR inhibitor, or PI3K inhibitor",
                                "requirement": {
                                    "requirement_type": "discontinuation reason",
                                    "expected_value": "disease progression"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Any significant co-morbidity that would impact the study or the subject's safety.",
                "criterions": [
                    {
                        "exact_snippets": "Any significant co-morbidity that would impact the study or the subject's safety.",
                        "criterion": "co-morbidity",
                        "requirement": {
                            "requirement_type": "significance",
                            "expected_value": "significant"
                        }
                    },
                    {
                        "exact_snippets": "Any significant co-morbidity that would impact the study or the subject's safety.",
                        "criterion": "co-morbidity",
                        "requirement": {
                            "requirement_type": "impact",
                            "expected_value": [
                                "study",
                                "subject's safety"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "10. History of malignancy within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery, or early stage cervical cancer.",
                "criterions": [
                    {
                        "exact_snippets": "History of malignancy within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery, or early stage cervical cancer.",
                        "criterion": "history of malignancy",
                        "requirement": {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "History of malignancy within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery, or early stage cervical cancer.",
                        "criterion": "history of malignancy",
                        "requirement": {
                            "requirement_type": "cancer type exclusion",
                            "expected_value": [
                                "breast cancer",
                                "basal cell carcinoma of the skin curatively treated by surgery",
                                "squamous cell carcinoma of the skin curatively treated by surgery",
                                "early stage cervical cancer"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "7. History of a pulmonary embolus (PE) or deep vein thrombosis (DVT) within the last 6 months or any known thrombophilia. Subjects stable on anti-coagulants for maintenance are eligible as long as the DVT and/or PE occurred >6 months prior to enrollment and there is no evidence for active thrombosis. The use of low dose ASA is permitted.",
                "criterions": [
                    {
                        "exact_snippets": "History of a pulmonary embolus (PE) or deep vein thrombosis (DVT) within the last 6 months",
                        "criterion": "history of pulmonary embolus (PE)",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "History of a pulmonary embolus (PE) or deep vein thrombosis (DVT) within the last 6 months",
                        "criterion": "history of deep vein thrombosis (DVT)",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "any known thrombophilia",
                        "criterion": "thrombophilia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Subjects stable on anti-coagulants for maintenance are eligible as long as the DVT and/or PE occurred >6 months prior to enrollment and there is no evidence for active thrombosis",
                        "criterion": "history of DVT and/or PE (on anti-coagulants for maintenance)",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Subjects stable on anti-coagulants for maintenance are eligible as long as the DVT and/or PE occurred >6 months prior to enrollment and there is no evidence for active thrombosis",
                        "criterion": "history of DVT and/or PE (on anti-coagulants for maintenance)",
                        "requirement": {
                            "requirement_type": "evidence for active thrombosis",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "The use of low dose ASA is permitted",
                        "criterion": "use of low dose ASA",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "or_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "History of a pulmonary embolus (PE) or deep vein thrombosis (DVT) within the last 6 months",
                                        "criterion": "history of pulmonary embolus (PE)",
                                        "requirement": {
                                            "requirement_type": "time since event",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 6,
                                                "unit": "months"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Subjects stable on anti-coagulants for maintenance are eligible as long as the DVT and/or PE occurred >6 months prior to enrollment and there is no evidence for active thrombosis",
                                        "criterion": "history of DVT and/or PE (on anti-coagulants for maintenance)",
                                        "requirement": {
                                            "requirement_type": "time since event",
                                            "expected_value": {
                                                "operator": ">",
                                                "value": 6,
                                                "unit": "months"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Subjects stable on anti-coagulants for maintenance are eligible as long as the DVT and/or PE occurred >6 months prior to enrollment and there is no evidence for active thrombosis",
                                        "criterion": "history of DVT and/or PE (on anti-coagulants for maintenance)",
                                        "requirement": {
                                            "requirement_type": "evidence for active thrombosis",
                                            "expected_value": false
                                        }
                                    }
                                ]
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "History of a pulmonary embolus (PE) or deep vein thrombosis (DVT) within the last 6 months",
                                        "criterion": "history of deep vein thrombosis (DVT)",
                                        "requirement": {
                                            "requirement_type": "time since event",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 6,
                                                "unit": "months"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Subjects stable on anti-coagulants for maintenance are eligible as long as the DVT and/or PE occurred >6 months prior to enrollment and there is no evidence for active thrombosis",
                                        "criterion": "history of DVT and/or PE (on anti-coagulants for maintenance)",
                                        "requirement": {
                                            "requirement_type": "time since event",
                                            "expected_value": {
                                                "operator": ">",
                                                "value": 6,
                                                "unit": "months"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Subjects stable on anti-coagulants for maintenance are eligible as long as the DVT and/or PE occurred >6 months prior to enrollment and there is no evidence for active thrombosis",
                                        "criterion": "history of DVT and/or PE (on anti-coagulants for maintenance)",
                                        "requirement": {
                                            "requirement_type": "evidence for active thrombosis",
                                            "expected_value": false
                                        }
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "exact_snippets": "any known thrombophilia",
                        "criterion": "thrombophilia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "failed_miscellaneous": []
}